NeuroMab™ Anti-NGF Antibody,Clone NR2676P

Product Overview

Description

E3 specifically binds to human and rodent nerve growth factor and strongly block the survival of trigeminal neurons dependent on human NGF.

Species Reactivity

Human; Rodent

Clonality

Monoclonal

Host Species

Humanized

Clone Number

NR2676P

Applications

FC; ELISA; Block; Inhib; In Vitro; In Vivo; Antagonist

Relevant Diseases

Alzheimer's Disease; Parkinson's Disease; Huntington's Disease; Multiple Sclerosis

Product Properties

Formulation

PBS only

Preservatives

BSA Free

Concentration

1mg/mL

Purification

Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line

Purity

>95% by SDS PAGE or HPLC

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only

Target

NGF

Official Name

NGF

Full Name

Nerve Growth Factor

Alternative Names

Nerve Growth Factor; Nerve Growth Factor (Beta Polypeptide); Beta-NGF; NGFB; Nerve Growth Factor; Beta Subunit; Beta-Nerve Growth Factor; HSAN5;

Gene ID

4803(Human); 18049(Mouse); 310738(Rat)

Uniprot ID

P01138(Human); P01139(Mouse); P25427(Rat)

Product Pictures

Block

Figure 1 is a graph comparing the NGF blocking effect of various Fabs in the presence of human NGF 0.04 ng/ml.

Elimination is measured using an antibody-dependent cellular cytotoxicity assay ("ADCC").

FuncS

Figure 2 is a graph showing rest pain evaluated 24 hours after surgery, showing that treatment with 0.02 mg/kg, 0.1 mg/kg, 0.6 mg/kg, and 1 mg/kg of anti-NGF E3 antibody reduced pain. "*" indicates a statistically significant difference (p < 0.5) from the negative control.

Elimination is measured using an antibody-dependent cellular cytotoxicity assay ("ADCC").

BIAcore

Figure 3 is a graph showing the results of BIAcore analysis of human NGF binding affinity of E3 (Fab) antibody (referred to as "Fab 3E"). E3 binds to human NGF with a KD of about 0.07 nM (kon about 6.0 x 105 M-1 s-1, koff about 4.2 x 10-5 s-1).

Elimination is measured using an antibody-dependent cellular cytotoxicity assay ("ADCC").

Block

Figure 4 is a graph showing that E3 antibody blocks the interaction of NGF with its receptors trkA and p75.

Axis corresponds to concentration of 3E antibody (Fab) and Y axis corresponds to NGF binding (percentage of maximal UR). Increasing concentrations of Fab E3 blocked the interaction of NGF with p75 and trkA, as indicated by a decrease in signal (measured in UR). When the concentration of E3 antibody (Fab) was equal to that of NGF, no NGF binding was observed (indicated by zero signal).

Inhib

Figure 5 is a graph showing the capacities of Antibody E3 (solid triangles; referred to as "3E"), Antibody 911 (solid circles) at different concentrations (20, 4, 0.8, 0.16, 0.032, 0.0064, 0.00128, and 0.0 nM) and The trkA receptor immunoadhesin (shaded squares; designated 'trkA-Fc') inhibits NGF-dependent survival of trigeminal neurons E13.5.

FuncS

Figure 6 is a graph showing the nociceptive response of arthritic rats (rheumatoid arthritis model) after administration of anti-NGF antibodies (E3 and 911) on D14 and D19.

FuncS

Figure 7 is a graph showing the effect of anti-NGF antibody on body weight of arthritic rats (rheumatoid arthritis model) after administration of anti-NGF antibody on D14 and D19.

Publications